PMID- 17914578
OWN - NLM
STAT- MEDLINE
DCOM- 20071213
LR  - 20161124
IS  - 1021-335X (Print)
IS  - 1021-335X (Linking)
VI  - 18
IP  - 5
DP  - 2007 Nov
TI  - New peptides of the polycomb group protein enhancer of zeste homolog 2 with the 
      potential to induce cancer-reactive cytotoxic T lymphocytes in human leukocyte 
      antigen-A2+ prostate cancer patients.
PG  - 1231-7
AB  - The polycomb group protein enhancer of zeste homolog 2 (EZH2) is linked to 
      aggressive prostate cancer and could be an appropriate target in specific 
      immunotherapy. In this study, we attempted to identify EZH2-derived peptides that 
      have the potential to generate cancer-reactive cytotoxic T lymphocytes (CTLs) in 
      human leukocyte antigen (HLA)-A2+ prostate cancer patients. Twelve EZH2-derived 
      peptides were prepared based on the HLA-A2 binding motif. These peptide 
      candidates were screened first by their ability to be recognized by 
      immunoglobulin G (IgG), and then by their ability to induce peptide-specific 
      cytotoxic T lymphocytes (CTLs). As a result, five EZH2 peptides recognized by IgG 
      (EZH2 120-128, EZH2 165-174, EZH2 569-577, EZH2 665-674, and EZH2 699-708) were 
      frequently detected in the plasma of prostate cancer patients. Among them, the 
      EZH2 120-128 and EZH2 165-174 peptides effectively induced HLA-A2-restricted and 
      cancer-reactive CTLs from prostate cancer patients. The cytotoxicity was mainly 
      dependent on EZH2 peptide-specific and HLA-A2-restricted CD8+ T cells. These 
      results indicate that these EZH2 120-128 and EZH2 165-174 peptides could be 
      promising candidates in peptide-based immunotherapy for HLA-A2+ prostate cancer 
      patients.
FAU - Itoh, Yukoh
AU  - Itoh Y
AD  - Department of Immunology, Kurume University School of Medicine, Fukuoka, Japan.
FAU - Komohara, Yoshihiro
AU  - Komohara Y
FAU - Komatsu, Nobukazu
AU  - Komatsu N
FAU - Minami, Takafumi
AU  - Minami T
FAU - Saito, Koujiro
AU  - Saito K
FAU - Noguchi, Masanori
AU  - Noguchi M
FAU - Itoh, Kyogo
AU  - Itoh K
FAU - Harada, Mamoru
AU  - Harada M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Oncol Rep
JT  - Oncology reports
JID - 9422756
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (HLA-A2 Antigen)
RN  - 0 (Peptide Fragments)
RN  - 0 (Transcription Factors)
RN  - EC 2.1.1.43 (EZH2 protein, human)
RN  - EC 2.1.1.43 (Enhancer of Zeste Homolog 2 Protein)
RN  - EC 2.1.1.43 (Polycomb Repressive Complex 2)
SB  - IM
MH  - CD8-Positive T-Lymphocytes/immunology
MH  - Cold Temperature
MH  - DNA-Binding Proteins/*immunology
MH  - Enhancer of Zeste Homolog 2 Protein
MH  - HLA-A2 Antigen/*immunology
MH  - Humans
MH  - Male
MH  - Peptide Fragments/immunology
MH  - Polycomb Repressive Complex 2
MH  - Prostatic Neoplasms/*immunology/physiopathology
MH  - T-Lymphocytes, Cytotoxic/*immunology
MH  - Transcription Factors/*immunology
EDAT- 2007/10/05 09:00
MHDA- 2007/12/14 09:00
CRDT- 2007/10/05 09:00
PHST- 2007/10/05 09:00 [pubmed]
PHST- 2007/12/14 09:00 [medline]
PHST- 2007/10/05 09:00 [entrez]
PST - ppublish
SO  - Oncol Rep. 2007 Nov;18(5):1231-7.